OpenLegislation

Paragraph 4 Insertion of regulation 27A (fee for renewals of a marketing authorisation)I1

United Kingdom

After regulation 27, insert—

“Fee for renewals of a marketing authorisation

27A

Where an application is made to the licensing authority for the renewal of a marketing authorisation F1in the case of a product for sale or supply in Great Britain and the application for renewal—

(a)

relates to a medicinal product which, at the time the marketing authorisation was granted, contained a new active ingredient; and

(b)

is the first renewal in relation to that product,

the fee payable by the applicant is the fee prescribed in Part 6 of Schedule 2.”.

Annotations

Textual amendments

F1

Words in Sch. 1 para. 4 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(e)

Commencement

I1

Sch. 1 para. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1